September 16, 2025

Lebrikizumab 24-Week Trial in Skin of Color Atopic Dermatitis

Lebrikizumab shows sustained efficacy across Fitzpatrick IV–VI at 24 weeks in atopic dermatitis.

Conexiant

September 12, 2025

FDA Considers Ending Routine Advisory Committees on New Drugs

The FDA move to limit advisory committee involvement in drug approvals has prompted debate on the balance between efficiency and transparency.

KFF Health News

September 09, 2025

Top 10 States to Practice Dermatology

The following list highlights the states that offer the most favorable conditions for dermatologists.

Conexiant

September 05, 2025

One Dose of Benzathine Penicillin Noninferior for Early Syphilis

Most patients reported local injection-site pain, but serious adverse events were rare and unrelated to benzathine penicillin G treatment.

Conexiant

August 28, 2025

Does Changing Biologics Clear Skin Faster?

The psoriasis treatment ladder may not apply to interclass biologic switching.

Conexiant

August 25, 2025

Did Politics Delay CDC Measles Response?

Emails and interviews show CDC scientists were sidelined during the West Texas surge, leaving local officials without guidance as cases spread across the US and into Mexico.

KFF Health News

August 22, 2025

Nemolizumab Study Tracks 68 Weeks of Relief

A long-term clinical study finds that the biologic therapy nemolizumab, when used with topical corticosteroids, continues to improve itch, sleep, and skin symptoms in prurigo nodularis patients over 68 weeks.

Conexiant

August 14, 2025

Dalbavancin Holds Its Own Against S. aureus Bacteremia, Study

"All treatments currently approved with an indication for bacteremia require prolonged intravenous access."

Conexiant

April 29, 2024

First Death From Alaskapox Reported

Alaska health officials warned of the risk of Alaskapox in the wake of the first death from the disease in January 2024.

Conexiant